• 1
    DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin dependent diabetes mellitus. N Engl J Med 1993;329:97786.
  • 2
    The DCCT/EDIC Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:264353.
  • 3
    Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the ADA and the EASD. Diabetes Care 2006;29:196372.
  • 4
    Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the ADA and the EASD. Diabetologia 2006;49:171121.
  • 5
    Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:40512.
  • 6
    Hirsch IB, Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control? J Diabetes Complications 2005;19:17881.
  • 7
    King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 1998;21:141431.
  • 8
    Boyle JP, Honeycutt AA, Narayan KM, et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care 2001;24:193640.
  • 9
    Dunstan DW, Zimmet PZ, Welborn TA, et al. The rising prevalence of diabetes and impaired glucose tolerance: the Australian diabetes, obesity and lifestyle study. Diabetes Care 2002;25:82934.
  • 10
    Kim JS, Kim YJ, Park SI, Hong YP. Mean fasting blood glucose level and an estimated prevalence of diabetes mellitus among a representative adult Korea population. Korean J Prev Med 1993;26:31120.
  • 11
    Mastrotorato J. The MiniMed continuous glucose monitoring system (CGMS). J Pediatr Endocrinol Metab 1999;12:7518.
  • 12
    The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008;359:146476.
  • 13
    American Diabetes Association. Standards of medical care in diabetes-2009. Diabetes Care 2011;32:S1161.
  • 14
    Raccah D, Sulmont V, Reznik Y, et al. Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the RealTrend study. Diabetes Care 2009;32:224550.
  • 15
    O’Connell MA, Donath S, O’Neal DN, et al. Glycaemic impact of patient-led use of sensor-guided pump therapy in type 1 diabetes: a randomised controlled trial. Diabetologia 2009;52:12507.
  • 16
    Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010;363:31120.
  • 17
    Lelio M, Alessandra DF, Angelo L, et al. Continuous subcutaneous insulin infusion (CSII) in inpatient setting: unmet needs and the proposal of a CSII unit. Diabetes Technol Ther 2011;13(10): 10714.
  • 18
    Hirsch IB, Abelseth J, Bode BW, et al. Sensor-augmented insulin pump therapy: results of the first randomized treat-totarget study. Diabetes Technol Ther 2008;10:37783.
  • 19
    Hermanides J, Nørgaard K, Bruttomesso D, et al. Sensor-augmented pump therapy lowers HbA(1c) in suboptimally controlled type 1 diabetes: a randomized controlled trial. Diabet Med 2011;28:11581167.
  • 20
    Hovorka R, Allen JM, Elleri D, et al. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. Lancet 2010;375:74351.
  • 21
    Murphy HR, Elleri D, Allen JM, et al. Closed-loop insulin delivery during pregnancy complicated by type 1 diabetes. Diabetes Care 2011;34:40611.
  • 22
    Chitayat L, Zisser H, Jovanovic L. Continuous glucose monitoring during pregnancy. Diabetes Technol Ther 2009;11(Suppl 1): S10511.
  • 23
    Kestila KK, Ekblad UU, Ronnemaa T. Continuous glucose monitoring versus self-monitoring of blood glucose in the treatment of gestational diabetes mellitus. Diabetes Res Clin Pract 2007;77:1749.
  • 24
    McLachlan K, Jenkins A, O’Neal D. The role of continuous glucose monitoring in clinical decision-making in diabetes in pregnancy. Aust N Z J Obstet Gynaecol 2007;47:18690.
  • 25
    Yogev Y, Ben-Haroush A, Chen R, Kaplan B, Phillip M, Hod M. Continuous glucose monitoring for treatment adjustment in diabetic pregnancies-a pilot study. Diabet Med 2003;20:55862.
  • 26
    Goldberg PA, Siegel MD, Russell RR, et al. Experience with the continuous glucose monitoring system in a medical intensive care unit. Diabetes Technol Ther 2004;6:33947.
  • 27
    Buckingham B, Cobry E, Clinton P, et al. Preventing hypoglycemia using predictive alarm algorithms and insulin pump suspension. Diabetes Technol Ther 2009;11:937.
  • 28
    The Diabetes Control and Complications Trial Research Group. Resource utilization and costs of care in the Diabetes Control and Complications Trial. Diabetes Care 1995;18:146878.
  • 29
    McQueen RB, Ellis SL, Campbell JD, Nair KV, Patrick W, Sullivan PW. Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes. Cost Eff Resour Alloc 2011:9(13): 18.
  • 30
    Amanda B, Perry B. The role of reimbursement in the adoption of continuous glucose monitors. J Diabetes Sci Technol 2009;3(4): 9925.
  • 31
    Ginsberg BH. The FDA Panel advises approval of the first continuous glucose sensor. Diabetes Technol Ther 1999;2:2034.
  • 32
    Baek YH, Jin HY, Lee KA, et al. The correlation and accuracy of glucose levels between interstitial fluid and venous plasma by continuous glucose monitoring system. Korean Diabetes J 2010;34:3508.
  • 33
    Wentholt IM, Vollebregt MA, Hart AA, Hoekstra JB, DeVries JH. Comparison of a needle-type and a microdialysis continuous glucose monitor in type 1 diabetic patients. Diabetes Care 2005;28:28716.
  • 34
    Cho JH, Kim HS, Han JH, et al. Ubiquitous diabetes management system via interactive communication based on information technologies: clinical effects and perspectives. Korean Diabetes J 2010;34:26774.
  • 35
    Cho JH, Choi YH, Kim HS, Lee JH, Yoon KH. Effectiveness and safety of a glucose data-filtering system with automatic response software to reduce the physician workload in managing type 2 diabetes. J Telemed Telecare 2011;17:25762.